Medical AI Raises￥100M in Extended Series B Round

(VCBeat) Feb. 24, 2021 -- Recently, Beijing-based Yizhun Intelligent Technology Co., Ltd. ("Medical AI") announced that it has extended its Series B round by an additional ￥100 million yuan, led by CITIC Medical Fund, with participation from the existing investor Zhongfu Yide. 

The fresh round of funding will be used towards the R&D of products, improvement of the core pipeline and hardware, market expansion of AI products in medical institutions at all levels, and the full coverage of digital medicine in the process of intelligent hospital construction.

With the original prospect of becoming "an efficient and accurate AI assistant for doctors in medical imaging", Medical AI has developed medical imaging devices in almost every field. Taking breast cancer as an example, Medical AI creatively launched the world's first AI-powered system based on real-time three-dimensional ultrasonic imaging technology -- the breast ultrasound intelligent analysis system. Together with the intelligent analysis system for mammography, Medical AI covers the whole process of breast detection and making breast cancer screening more convenient.

Medical AI has built a fruitful product matrix based on CT, DR, MRI, ultrasound, breast molybdenum target, and others. To meet the needs of scientific research, Medical AI has launched the Darwin Scientific Research Platform, which integrates deep learning and omics imaging to build a one-stop scientific research platform from labeling to modeling. The platform has become an indispensable tool in medical scientific research by minimizing the technical threshold.

Up to now, Medical AI's products have been applied in more than 600 medical institutions in China, serving nearly 10,000 doctors to do detection, with the increase of the market share and the leading commercialization progress.

CITIC Medical Fund is CITIC's equity investment platform focusing on the medical field. It is committed to building a comprehensive enabling medical industry fund. Its team consists of industry professionals with many years of experience in multinational medical companies and experts with deep experience in the financial field.